Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03601819
Title	Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	University of Michigan Rogel Cancer Center
Indications	peripheral T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma splenic marginal zone lymphoma mantle cell lymphoma lymphoplasmacytic lymphoma chronic lymphocytic leukemia
Therapies	Pacritinib
Age Groups:	adult \| senior
Covered Countries	USA